Welcome to our dedicated page for NeOnc Technologies Holdings SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeOnc Technologies’ SEC documents are dense with clinical data, FDA milestones, and detailed R&D cost breakdowns—facts critical to anyone tracking its blood-brain-barrier therapies yet hard to locate in a 300-page 10-K. If you have ever asked, “How do I decode NeOnc Technologies SEC filings explained simply?” this page is built for you.
Stock Titan’s AI reads every disclosure the moment it hits EDGAR, then delivers plain-English takeaways. Whether you need the cash-runway table hidden in a NeOnc Technologies quarterly earnings report 10-Q filing or real-time alerts on NeOnc Technologies Form 4 insider transactions, our platform surfaces the numbers and context—fast. All filing types are covered and refreshed continuously:
- 10-K annual report—NeOnc Technologies annual report 10-K simplified with trial timelines and risk factors highlighted
- 10-Q—side-by-side revenue and R&D trend analysis for each quarter
- 8-K—NeOnc Technologies 8-K material events explained, from FDA designations to financing updates
- Form 4—NeOnc Technologies insider trading Form 4 transactions mapped to executive roles, plus push alerts for NeOnc Technologies executive stock transactions Form 4
- DEF 14A—NeOnc Technologies proxy statement executive compensation details with AI benchmarks
Use our summaries to compare Phase II spending quarter-over-quarter, monitor management sentiment before readouts, or answer “What did NeOnc disclose about its NEO platform revenue prospects?” Stop skimming dense PDFs—understanding NeOnc Technologies SEC documents with AI takes minutes, not hours, and delivers the insight needed for confident decisions.
NeOnc Technologies Holdings, Inc. completed a Nasdaq listing in March 2025 and received $11,644,005 from private placement commitments held in escrow until its registration became effective. For the three and six months ended June 30, 2025, the company reported net losses of $5,680,170 and $38,006,186, respectively, and an accumulated deficit of $88,614,631 at June 30, 2025. Shares outstanding were 19,026,776 at June 30, 2025 (18,090,526 at December 31, 2024). The company has material related-party obligations including an accrued advisory fee balance of $5,882,710 and an unpaid litigation settlement payable of $4,000,000. Financing activity includes bridge and promissory note arrangements with original issue discounts and subsequent issuance of promissory notes totaling $4,000,000 as of August 13, 2025. The filing discloses significant accumulated losses, ongoing financing arrangements, and contingent obligations that affect liquidity.
NeOnc Technologies Holdings, Inc. disclosed two material corporate developments. On August 7, 2025 the company announced it was awarded $2.5 million in NIH STTR grants to advance its drug candidate NEO212 for gliomas and leukemia; the announcement is furnished as Exhibit 99.1. On August 11, 2025 NeOnc announced the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market; that announcement is furnished as Exhibit 99.2.
The filing notes these press releases are furnished (not deemed "filed") for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings except as expressly stated. The company’s common stock trades as NTHI on Nasdaq and it is identified as an emerging growth company in the filing.
FAQ
What is the current stock price of NeOnc Technologies Holdings (NTHI)?
What is the market cap of NeOnc Technologies Holdings (NTHI)?
